ODT in BE study [Design Issues]

posted by Farmacevt – North Macedonia, 2022-01-18 16:01 (129 d 00:22 ago) – Posting: # 22732
Views: 600


I would appreciate if you can share your opinion regarding this particular case:

IF you develop generic orodispersible tablet (ODT) and the reference formulation is immediate release tablet (obviously it can be administrate only with water) is it enough to perform two way cross-over study where the ODT will be administrated without water and the reference tbl. with water, or 3 arm study (ODT administrated in both ways with and without water and the reference with water) should be performed?

Thank you

Complete thread:

UA Flag
 Admin contact
22,108 posts in 4,630 threads, 1,567 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Friday 17:24 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz